MX2019013982A - Construccion de expresion viral que comprende una secuencia codificadora del factor de crecimiento de fibroblastos 21 (fgf21). - Google Patents

Construccion de expresion viral que comprende una secuencia codificadora del factor de crecimiento de fibroblastos 21 (fgf21).

Info

Publication number
MX2019013982A
MX2019013982A MX2019013982A MX2019013982A MX2019013982A MX 2019013982 A MX2019013982 A MX 2019013982A MX 2019013982 A MX2019013982 A MX 2019013982A MX 2019013982 A MX2019013982 A MX 2019013982A MX 2019013982 A MX2019013982 A MX 2019013982A
Authority
MX
Mexico
Prior art keywords
fgf21
growth factor
fibroblast growth
expression construct
coding sequence
Prior art date
Application number
MX2019013982A
Other languages
English (en)
Spanish (es)
Inventor
Cenzano Verónica Jiménez
Tubert Fatima Bosch
Pallares Claudia Jambrina
Original Assignee
Univ Autonoma De Barcelona Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Autonoma De Barcelona Star filed Critical Univ Autonoma De Barcelona Star
Publication of MX2019013982A publication Critical patent/MX2019013982A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/25—Animals on a special diet
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019013982A 2017-05-24 2018-05-24 Construccion de expresion viral que comprende una secuencia codificadora del factor de crecimiento de fibroblastos 21 (fgf21). MX2019013982A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17172818 2017-05-24
ES201700615 2017-05-24
PCT/EP2018/063707 WO2018215613A1 (fr) 2017-05-24 2018-05-24 Construction d'expression virale comprenant une séquence de codage du facteur de croissance des fibroblastes 21 (fgf21)

Publications (1)

Publication Number Publication Date
MX2019013982A true MX2019013982A (es) 2020-07-22

Family

ID=62620819

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013982A MX2019013982A (es) 2017-05-24 2018-05-24 Construccion de expresion viral que comprende una secuencia codificadora del factor de crecimiento de fibroblastos 21 (fgf21).

Country Status (9)

Country Link
US (1) US20200102361A1 (fr)
EP (1) EP3630160A1 (fr)
JP (2) JP2020530977A (fr)
CN (1) CN110913886A (fr)
AU (1) AU2018274655A1 (fr)
BR (1) BR112019024608A2 (fr)
MX (1) MX2019013982A (fr)
RU (1) RU2019142845A (fr)
WO (1) WO2018215613A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019389253A1 (en) * 2018-11-26 2021-06-10 Universitat Autonoma De Barcelona Fibroblast growth factor 21 (FGF21) gene therapy
EP4252783A3 (fr) * 2019-07-10 2023-11-15 Masonic Medical Research Laboratory Vgll4 avec un élément régulateur cis d'ucp-1 et son procédé d'utilisation
MX2022014754A (es) * 2020-05-26 2023-01-16 UNIV AUTòNOMA DE BARCELONA Terapia genica del factor de crecimiento de fibroblastos 21 (fgf21) para trastornos del sistema nervioso central.
CN113956344A (zh) * 2021-10-14 2022-01-21 江南大学 一种新型治疗肝癌的fgf类似物及其应用
CN114010666B (zh) * 2021-10-22 2024-05-07 上海交通大学 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用
CN114316018A (zh) * 2021-11-26 2022-04-12 江南大学 一种fgf21蛋白类似物及其应用
CN117247973B (zh) * 2022-04-19 2024-05-10 康霖生物科技（杭州）有限公司 一种用于遗传性凝血因子缺乏病治疗的核酸构建体及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
ES2224375T3 (es) 1997-04-14 2005-03-01 Cell Genesys, Inc. Metodos para aumentar la eficacia del producto de aav recombinante.
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
JP4390860B2 (ja) 1997-05-13 2009-12-24 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル レンチウイルスをベースにした遺伝子転移ベクター
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
EP1080218A1 (fr) 1998-05-27 2001-03-07 University of Florida Procede de preparation de compositions de virus adeno-associes de recombinaison a l'aide d'un gradient d'iodixananol
EP1135468B1 (fr) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Vecteurs viraux et leurs procedes d'elaboration et d'administration
DE19909769A1 (de) 1999-03-05 2000-09-07 Bundesrepublik Deutschland Let Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen
EP1286703B1 (fr) 2000-06-01 2009-08-05 University Of North Carolina At Chapel Hill Procedes et composes pour la liberation controlee de vecteurs de parvovirus de recombinaison
WO2002024234A2 (fr) * 2000-09-20 2002-03-28 The Regents Of The University Of California Utilisation de vecteurs recombines d'administration genique pour traiter ou prevenir des maladies de l'oeil
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
CN113683705A (zh) * 2011-07-01 2021-11-23 恩格姆生物制药公司 用于代谢病症和疾病治疗的组合物、应用和方法
EP2750695A2 (fr) * 2011-08-31 2014-07-09 Amgen Inc. Procédé de traitement ou d'amélioration du diabète type i employant fgf21
EP2692868A1 (fr) * 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Vecteurs viraux adéno-associés (AAV) utiles pour la transduction de tissu adipeux
NZ630484A (en) * 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) * 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
CN105916990B (zh) * 2013-08-02 2020-02-04 巴塞罗那自治大学 用于转导脂肪组织的腺相关病毒载体
US20190345224A1 (en) * 2016-05-20 2019-11-14 President And Fellows Of Harvard College Gene Therapy Methods for Age-Related Diseases and Conditions
AU2019389253A1 (en) * 2018-11-26 2021-06-10 Universitat Autonoma De Barcelona Fibroblast growth factor 21 (FGF21) gene therapy

Also Published As

Publication number Publication date
WO2018215613A1 (fr) 2018-11-29
RU2019142845A (ru) 2021-06-24
AU2018274655A1 (en) 2019-12-19
US20200102361A1 (en) 2020-04-02
CN110913886A (zh) 2020-03-24
JP2020530977A (ja) 2020-11-05
EP3630160A1 (fr) 2020-04-08
JP2023109992A (ja) 2023-08-08
RU2019142845A3 (fr) 2021-09-20
BR112019024608A2 (pt) 2020-06-23

Similar Documents

Publication Publication Date Title
MX2019013982A (es) Construccion de expresion viral que comprende una secuencia codificadora del factor de crecimiento de fibroblastos 21 (fgf21).
SA517390590B1 (ar) Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة
MX2017004488A (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
MX2020004578A (es) Composiciones de casz y metodos de uso.
WO2017077329A3 (fr) Acides nucléiques, peptides et méthodes
BR112017003406A2 (pt) genoma de chromobacterium subtsugae
MX2016003944A (es) Composiciones y formulaciones para mantener y aumentar la masa muscular, fuerza y rendimiento y metodos de produccion y usos de los mismos.
MX2022001971A (es) Polipeptidos de interleucina 2 (il-2) modificados, conjugados y usos de los mismos.
AR092076A1 (es) Proteinas homodimericas
WO2015183890A3 (fr) Méthodes et compositions pour le traitement de maladies et de troubles métaboliques
NZ628625A (en) Polypeptides binding to human complement c5
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
UY36578A (es) Proteínas de unión a tslp
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
EP3943092A3 (fr) Compositions destinées à induire la différentiation de progéniteurs des adipocytes bruns humains
WO2018118997A3 (fr) Enzymes de polymérisation pour des réactions de séquençage
NZ595361A (en) Chimeric factor h binding proteins (fhbp) and methods of use
AR110093A1 (es) D-psicosa 3-epimerasa y método para preparar d-psicosa utilizando la misma
ZA202302340B (en) Compositions and methods for treating celiac sprue disease
PH12019501193A1 (en) Use of chelating agents for improving color stability of resorcinol
IN2015DN03206A (fr)
MX2023000804A (es) Peptidos para usarse en la promocion del transporte de glucosa.
MY194351A (en) Recombinant Human-Basic Fibroblast Growth Factor (Rh-Bfgf) and Pharmaceutical Composition Comprising Rh-Bfgf
MX2020000414A (es) Composicion de vacuna de neoantigeno para el tratamiento del cancer.
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof